Mebeverine – an effective spasmolytic in the treatment of IBS Review article
Article Sidebar
Published:
Nov 30, 2023
Keywords:
irritable bowel syndrome, gut–brain axis disorders, spasmolytics, mebeverine
Main Article Content
Abstract
Irritable bowel syndrome (IBS) is a chronic disease classified as a disorder of the gut–brain axis. The pathophysiology is multifactorial and includes: dysfunction of the gut–brain axis, changes in the composition of the intestinal microbiota and mental disorders. In addition to non-pharmacological treatment, antispasmodics play an important role in the treatment. Spasmolytics are agents with proven effectiveness and safety in IBS. Mebeverine is a drug with a long tradition of use, proven effectiveness and good tolerance. It is indicated in any form of IBS, with the dominance of symptoms such as abdominal pain and flatulence.
Article Details
How to Cite
Witek, P., & Waluga, M. (2023). Mebeverine – an effective spasmolytic in the treatment of IBS. Medycyna Faktow (J EBM), 16(3(60), 338-343. https://doi.org/10.24292/01.MF.0323.10
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Mo-til. 2017; 23(2): 151-63. http://doi.org/10.5056/jnm16214.
2. Sperber AD, Bangdiwala SI, Drossman DA et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021; 160(1): 99-114.e3. http://doi.org/10.1053/j.gastro.2020.04.014.
3. Cassar GE, Youssef GJ, Knowles S et al. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2020; 43(3): E102-22. http://doi.org/10.1097/SGA.0000000000000530.
4. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014; 40(9): 1023-34. http://doi.org/10.1111/apt.12938.
5. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016; 1(2): 133-46. http://doi.org/10.1016/S2468-1253(16)30023-1.
6. Berumen A, Edwinson AL, Grover M. Post-infection Irritable Bowel Syndrome. Gastroenterol Clin North Am. 2021; 50(2): 445-61. http://doi.org/10.1016/j.gtc.2021.02.007.
7. Mari A, Abu Baker F, Mahamid M et al. The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. J Clin Med. 2020; 9(3): 685. http://doi.org/10.3390/jcm9030685.
8. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Feb 19: S0016-5085(16)00223-7. http://doi.org/10.1053/j.gastro.2016.02.032.
9. David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014; 505(7484): 559-63. http://doi.org/10.1038/nature12820.
10. Shepherd SJ, Parker FC, Muir JG et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008; 6(7): 765-71. http://doi.org/10.1016/j.cgh.2008.02.058.
11. Tana C, Umesaki Y, Imaoka A et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010; 22(5): 512-9, e114-5. http://doi.org/10.1111/j.1365-2982.2009.01427.x.
12. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol. 2018; 13(4): 259-88. http://doi.org/10.5114/pg.2018.78343.
13. Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc. 2018; 93(12): 1858-72. http://doi.org/10.1016/j.mayocp.2018.04.032.
14. Alammar N, Stein E. Irritable Bowel Syndrome: What Treatments Really Work. Med Clin North Am. 2019; 103(1): 137-52. http://doi.org/10.1016/j.mcna.2018.08.006.
15. Johannesson E, Simrén M, Strid H et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011; 106(5): 915-22. http://doi.org/10.1038/ajg.2010.480.
16. van Lanen AS, de Bree A, Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr. 2021; 60(6): 3505-22. http://doi.org/10.1007/s00394-020-02473-0. Erratum in: Eur J Nutr. 2021 Jun 28.
17. Skrzydło-Radomańska B, Szczepanek M, Bartnik W. Zespół jelita drażliwego. Online. (access: 18.05.2023).
18. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001; 15(3): 355-61. http://doi.org/10.1046/j.1365-2036.2001.00937.x.
19. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012; 77(2): 82-90. http://doi.org/10.1016/j.rgmx.2012.04.002.
20. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B et al. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome – A Systematic Review. J Clin Med. 2022; 11(4): 1044. http://doi.org/10.3390/jcm11041044.
21. Annaházi A, Róka R, Rosztóczy A et al. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014; 20(20): 6031-43. http://doi.org/10.3748/wjg.v20.i20.6031.
22. Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther. 1996; 10(5): 787-93. http://doi.org/10.1046/j.1365-2036.1996.61203000.x.
23. Rahman MZ, Ahmed DS, Mahmuduzzaman M et al. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Mymensingh Med J. 2014; 23(1): 105-13.
24. Lüttecke K. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin. 1980; 6: 437-43. http://doi.org/10.1185/03007998009109464.
25.Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010; 16(5): 547-53. http://doi.org/10.3748/wjg.v16.i5.547.
26. Drossman DA, Patrick DL, Whitehead WE et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000; 95(4): 999-1007. http://doi.org/10.1111/j.1572-0241.2000.01941.x.
27. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34(11): 783-93. http://doi.org/10.1007/s40261-014-0233-y.
28. Gilbody JS, Fletcher CP, Hughes IW et al. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract. 2000; 54(7): 461-4.
29. Winsemius A, Meuwsen IM, Boon C et al. A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine. Int J Clin Pract. 2002; 56(9): 659-62.
30. Savarino E, Zingone F, Barberio B et al. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterol J. 2022; 10(6): 556-84. http://doi.org/10.1002/ueg2.12259.
31. Chapman MA, Grahn MF, Boyle MA et al. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut. 1994; 35(1): 73-6. http://doi.org/10.1136/gut.35.1.73.
32. Lewandowski K, Kaniewska M, Karłowicz K et al. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Prz Gastroenterol. 2022; 17(1): 28-34. http://doi.org/10.5114/pg.2021.112681.
33. Banasiewicz T, Kaczmarek E, Maik J et al. Wpływ chronionego maślanu sodu na częstość i nasilenie wybranych objawów klinicznych u chorych z zespołem jelita nadwrażliwego. Gastroenterologia Praktyczna. 2012; 1(14): 48-55.
2. Sperber AD, Bangdiwala SI, Drossman DA et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021; 160(1): 99-114.e3. http://doi.org/10.1053/j.gastro.2020.04.014.
3. Cassar GE, Youssef GJ, Knowles S et al. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2020; 43(3): E102-22. http://doi.org/10.1097/SGA.0000000000000530.
4. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014; 40(9): 1023-34. http://doi.org/10.1111/apt.12938.
5. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016; 1(2): 133-46. http://doi.org/10.1016/S2468-1253(16)30023-1.
6. Berumen A, Edwinson AL, Grover M. Post-infection Irritable Bowel Syndrome. Gastroenterol Clin North Am. 2021; 50(2): 445-61. http://doi.org/10.1016/j.gtc.2021.02.007.
7. Mari A, Abu Baker F, Mahamid M et al. The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. J Clin Med. 2020; 9(3): 685. http://doi.org/10.3390/jcm9030685.
8. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Feb 19: S0016-5085(16)00223-7. http://doi.org/10.1053/j.gastro.2016.02.032.
9. David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014; 505(7484): 559-63. http://doi.org/10.1038/nature12820.
10. Shepherd SJ, Parker FC, Muir JG et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008; 6(7): 765-71. http://doi.org/10.1016/j.cgh.2008.02.058.
11. Tana C, Umesaki Y, Imaoka A et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010; 22(5): 512-9, e114-5. http://doi.org/10.1111/j.1365-2982.2009.01427.x.
12. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol. 2018; 13(4): 259-88. http://doi.org/10.5114/pg.2018.78343.
13. Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc. 2018; 93(12): 1858-72. http://doi.org/10.1016/j.mayocp.2018.04.032.
14. Alammar N, Stein E. Irritable Bowel Syndrome: What Treatments Really Work. Med Clin North Am. 2019; 103(1): 137-52. http://doi.org/10.1016/j.mcna.2018.08.006.
15. Johannesson E, Simrén M, Strid H et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011; 106(5): 915-22. http://doi.org/10.1038/ajg.2010.480.
16. van Lanen AS, de Bree A, Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr. 2021; 60(6): 3505-22. http://doi.org/10.1007/s00394-020-02473-0. Erratum in: Eur J Nutr. 2021 Jun 28.
17. Skrzydło-Radomańska B, Szczepanek M, Bartnik W. Zespół jelita drażliwego. Online. (access: 18.05.2023).
18. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001; 15(3): 355-61. http://doi.org/10.1046/j.1365-2036.2001.00937.x.
19. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012; 77(2): 82-90. http://doi.org/10.1016/j.rgmx.2012.04.002.
20. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B et al. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome – A Systematic Review. J Clin Med. 2022; 11(4): 1044. http://doi.org/10.3390/jcm11041044.
21. Annaházi A, Róka R, Rosztóczy A et al. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014; 20(20): 6031-43. http://doi.org/10.3748/wjg.v20.i20.6031.
22. Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther. 1996; 10(5): 787-93. http://doi.org/10.1046/j.1365-2036.1996.61203000.x.
23. Rahman MZ, Ahmed DS, Mahmuduzzaman M et al. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Mymensingh Med J. 2014; 23(1): 105-13.
24. Lüttecke K. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin. 1980; 6: 437-43. http://doi.org/10.1185/03007998009109464.
25.Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010; 16(5): 547-53. http://doi.org/10.3748/wjg.v16.i5.547.
26. Drossman DA, Patrick DL, Whitehead WE et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000; 95(4): 999-1007. http://doi.org/10.1111/j.1572-0241.2000.01941.x.
27. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34(11): 783-93. http://doi.org/10.1007/s40261-014-0233-y.
28. Gilbody JS, Fletcher CP, Hughes IW et al. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract. 2000; 54(7): 461-4.
29. Winsemius A, Meuwsen IM, Boon C et al. A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine. Int J Clin Pract. 2002; 56(9): 659-62.
30. Savarino E, Zingone F, Barberio B et al. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterol J. 2022; 10(6): 556-84. http://doi.org/10.1002/ueg2.12259.
31. Chapman MA, Grahn MF, Boyle MA et al. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut. 1994; 35(1): 73-6. http://doi.org/10.1136/gut.35.1.73.
32. Lewandowski K, Kaniewska M, Karłowicz K et al. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Prz Gastroenterol. 2022; 17(1): 28-34. http://doi.org/10.5114/pg.2021.112681.
33. Banasiewicz T, Kaczmarek E, Maik J et al. Wpływ chronionego maślanu sodu na częstość i nasilenie wybranych objawów klinicznych u chorych z zespołem jelita nadwrażliwego. Gastroenterologia Praktyczna. 2012; 1(14): 48-55.